The global clinical trial landscape of PD-1-containing bispecific antibodies for gastric cancer: current status and future directions of targeting immune tolerance - Top-Institutions - MDSpire

The global clinical trial landscape of PD-1-containing bispecific antibodies for gastric cancer: current status and future directions of targeting immune tolerance

  • By

  • Ziyue Sha

  • Zhengzheng Ji

  • Lanqing Zhao

  • Song Wang

  • Zhanjun Guo

  • June 22, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Milan
    University of Milan

    Milan, Lombardy

    Key Differentiators

    • Oncology

  • #2

    European Institute of Oncology
    European Institute of Oncology

    Milan, Lombardy

    Key Differentiators

    • Oncology

  • #3

    Institut Gustave Roussy
    Institut Gustave Roussy

    Villejuif, Île-de-France

    Key Differentiators

    • Oncology

  • #4

    University Hospitals Leuven
    University Hospitals Leuven

    Leuven, Flanders

    Key Differentiators

    • Oncology

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

Original Source(s)

The global clinical trial landscape of PD-1-containing bispecific antibodies for gastric cancer: current status and future directions of targeting immune tolerance

  • by Ziyue Sha, Zhengzheng Ji, Lanqing Zhao, Song Wang, Zhanjun Guo

  • June 22, 2026

Related Content

Prostatic incidental uptake on PET/CT: an updated systematic review and meta-analysis of prevalence and malignancy risk

Comparing the i31-SLNB and the MIA Nomogram for Sentinel Lymph Node Biopsy Positivity Prediction in Cutaneous Melanoma: A Prospective Cohort Analysis

Distribution analysis of gynecological carcinomas with concurrent second primary carcinomas